Home › NDC Lookup › RxCUI directory › RxCUI 876214

Polyethylene glycol 3350 17000 MG Powder for Oral Solution [Gavilax] — RxCUI 876214

RxNorm drug concept · Semantic branded drug
RxCUI 876214 Semantic branded drug · SBD ● Current RxNorm concept 6 FDA products 16 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI876214
Official namePolyethylene glycol 3350 17000 MG Powder for Oral Solution [Gavilax]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asGavilax 17 GM Powder for Oral Solution
FDA products mapped6
Package NDCs mapped16
Reported Medicaid activity (SDUD)229,473 prescriptions · 44 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Polyethylene Glycol 3350: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • You can generally expect a bowel movement within 1 to 3 days after taking it. It's not meant to work in an hour like some other laxatives — it works gradually. If you haven't gone...
  • How long does it take for Polyethylene Glycol 3350 to work?
  • You can stir it into any 4 to 8 ounces of beverage — water, juice, coffee, tea, whatever you like, cold or hot. The key is to stir it well until it's completely dissolved. Don't dr...
  • Can I mix it into any drink, or does it have to be water?
📖 Read our full Polyethylene Glycol 3350 guide →

🕸️ Concept Web — How Polyethylene glycol 3350 17000 MG Powder for Ora... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Polyethylene glycol 3350 17000 MG Powder for Oral Solution [Gavilax] RxCUI 876214

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Polyethylene glycol 3350 221147
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Gavilax 876188
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Polyethylene glycol 3350 Powder for Oral Solution 1870358
    • Polyethylene glycol 3350 Oral Powder Product 1870357
    • Polyethylene glycol 3350 Oral Product 1162922
    • Polyethylene glycol 3350 Powder for Oral Solution [Gavilax] 1870369
    • Gavilax Oral Powder Product 1870370
    • Gavilax Oral Product 1166511
    • Powder for Oral Solution 1540455
    • Oral Powder Product 1294711
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Polyethylene glycol 3350 17000 MG Powder for Oral Solution SCD · 876193
  • Polyethylene glycol 3350 17000 MG SCDC · 1870356
  • Polyethylene glycol 3350 Powder for Oral Solution SCDF · 1870358
  • Polyethylene glycol 3350 Oral Powder Product SCDG · 1870357
  • Polyethylene glycol 3350 Oral Product SCDG · 1162922

Brand-Name Concepts

  • Polyethylene glycol 3350 17000 MG [Gavilax] SBDC · 1870368
  • Polyethylene glycol 3350 Powder for Oral Solution [Gavilax] SBDF · 1870369
  • Gavilax Oral Powder Product SBDG · 1870370
  • Gavilax Oral Product SBDG · 1166511
  • Gavilax BN · 876188

📦 FDA Products & Package NDCs

6 products · 16 package NDCs
16 package NDCs map to RxCUI 876214 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
17856-0310-01 50 CUP, UNIT-DOSE in 1 CASE (17856-0310-1) / 2 g in 1 CUP,... GAVILAX Atlantic Biologicals Corp. 2026-06-01
17856-0310-02 72 POUCH in 1 CASE (17856-0310-2) / 2 g in 1 POUCH GAVILAX Atlantic Biologicals Corp. 2026-03-03
17856-0312-01 17 g in 1 BAG (17856-0312-1) GAVILAX ATLANTIC BIOLOGICALS CORP. 2021-01-26
17856-0312-02 8.5 g in 1 BAG (17856-0312-2) GAVILAX ATLANTIC BIOLOGICALS CORP. 2021-01-26
17856-0312-03 17 g in 1 CUP (17856-0312-3) GAVILAX ATLANTIC BIOLOGICALS CORP. 2021-01-26
17856-0312-04 4 g in 1 BAG (17856-0312-4) GAVILAX ATLANTIC BIOLOGICALS CORP. 2021-01-26
17856-0312-05 50 CUP in 1 CASE (17856-0312-5) / 8.5 g in 1 CUP GAVILAX ATLANTIC BIOLOGICALS CORP. 2021-01-26
17856-0312-06 72 POUCH in 1 CASE (17856-0312-6) / 4.5 g in 1 POUCH GAVILAX ATLANTIC BIOLOGICALS CORP. 2021-01-26
17856-0312-07 50 BAG in 1 BOX, UNIT-DOSE (17856-0312-7) / 4.25 g in 1 BAG GAVILAX ATLANTIC BIOLOGICALS CORP. 2023-10-10
17856-0312-08 72 BAG in 1 BOX, UNIT-DOSE (17856-0312-8) / 4.25 g in 1 BAG GAVILAX ATLANTIC BIOLOGICALS CORP. 2025-07-22
17856-0312-09 50 CUP in 1 BOX, UNIT-DOSE (17856-0312-9) / 4.25 g in 1 CUP GAVILAX ATLANTIC BIOLOGICALS CORP. 2025-07-22
43386-0312-08 238 g in 1 BOTTLE (43386-312-08) GAVILAX Lupin Pharmaceuticals,Inc. 2009-10-09
43386-0312-14 510 g in 1 BOTTLE (43386-312-14) GAVILAX Lupin Pharmaceuticals,Inc. 2009-10-09
50090-5310-00 238 g in 1 BOTTLE (50090-5310-0) GAVILAX A-S Medication Solutions 2020-10-28
63187-0368-23 238 g in 1 BOTTLE (63187-368-23) GAVILAX Proficient Rx LP 2016-09-01
68788-7508-02 238 g in 1 BOTTLE (68788-7508-2) GAVILAX Preferred Pharmaceuticals, Inc. 2019-10-28
Observed labelers: Atlantic Biologicals Corp. (11) · Lupin Pharmaceuticals,Inc. (2) · A-S Medication Solutions (1) · Preferred Pharmaceuticals, Inc. (1) · Proficient Rx LP (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per gm · median
$0.0225
Range $0.0204–$0.0245 · middle 50% $0.0214–$0.0235 · 2 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.